Avoidant/Restrictive Food Intake Disorder (ARFID): Disease Characteristics Report

Executive summary

Avoidant/restrictive food intake disorder (ARFID) is a psychiatric feeding/eating disorder in which persistent restriction of food quantity or variety causes clinically important nutritional, growth, medical, supplement-dependence, or psychosocial consequences without restriction being driven primarily by weight or shape concerns. The three canonical presentations—sensory sensitivity, lack of interest/low appetite, and fear of aversive consequences—are dimensions that frequently overlap rather than mutually exclusive subtypes. In a 2024 UK/Republic of Ireland surveillance study of 319 clinically diagnosed young people, the largest class was a combined sensory/lack-of-interest presentation (38.2%). (fonseca2024avoidantrestrictivefood pages 1-2, sanchezcerezo2024subtypesofavoidantrestrictive pages 1-2)

Current understanding favors a multifactorial developmental disorder involving sensory processing, appetite/homeostatic signaling, fear learning/negative valence, neurodevelopmental vulnerability, medical experiences, and family/environmental reinforcement. No monogenic cause, pathogenic variant, diagnostic molecular biomarker, or disease-specific drug has been established. Treatment is therefore individualized and multidisciplinary, with nutritional rehabilitation plus exposure-based cognitive-behavioral therapy or family-based treatment providing the most promising evidence. Most efficacy evidence nevertheless remains from case series, uncontrolled studies, and recently completed trials whose definitive results are not yet widely published. (fonseca2024avoidantrestrictivefood pages 13-14, fonseca2024avoidantrestrictivefood pages 12-13, fonseca2024avoidantrestrictivefood pages 4-6)

The following table summarizes the highest-yield evidence.

Table: This compact table summarizes the best available current evidence for avoidant/restrictive food intake disorder across definition, subtypes, epidemiology, mechanisms, diagnostics, treatment, and trials. It emphasizes where evidence is strongest and where important limitations remain.

1. Disease information

Definition and scope

DSM-5 introduced ARFID in 2013 as the successor to and expansion of “feeding disorder of infancy or early childhood.” It includes children, adolescents, and adults. Criterion A requires an eating/feeding disturbance with persistent failure to meet nutritional or energy needs and at least one of: significant weight loss or failure to grow appropriately; significant nutritional deficiency; dependence on oral supplements or enteral feeding; or marked interference with psychosocial functioning. Restriction cannot be adequately explained by unavailable food or culturally sanctioned practice, cannot occur exclusively during anorexia nervosa or bulimia nervosa, and is not driven by body-weight or shape disturbance. If another medical or psychiatric disorder is present, restriction must exceed what that condition ordinarily explains and independently require clinical attention. (fonseca2024avoidantrestrictivefood pages 1-2, sanchezcerezo2024subtypesofavoidantrestrictive pages 1-2, sanchezcerezo2024subtypesofavoidantrestrictive pages 3-4)

Direct abstract wording: Sanchez-Cerezo et al. described ARFID as “persistent disturbance in feeding or eating” causing inability to meet nutritional/energy needs, while emphasizing that it “is not associated with concerns about gaining weight nor with a preoccupation about body weight, shape, or size.” The study was published in eClinicalMedicine in February 2024; DOI: https://doi.org/10.1016/j.eclinm.2024.102440. (sanchezcerezo2024subtypesofavoidantrestrictive pages 1-2)

Identifiers and synonyms

• MeSH: Avoidant Restrictive Food Intake Disorder, D000080146. (NCT06110806 chunk 2)
• ICD-11: ARFID is recognized as a feeding or eating disorder; the commonly used ICD-11 code is 6B83.
• ICD-10-CM: F50.82, Avoidant/restrictive food intake disorder.
• DSM-5/DSM-5-TR: Avoidant/restrictive food intake disorder.
• MONDO: A stable MONDO identifier was not verified in the retrieved authoritative material; populate only after direct confirmation from the current MONDO release.
• OMIM/Orphanet: No disease-specific entry is expected because ARFID is neither an established Mendelian disease nor conventionally classified as a rare genetic disorder.
• Synonyms: avoidant/restrictive food intake disorder; avoidant restrictive food intake disorder; ARFID; historically, selective eating disorder. “Picky eating,” food neophobia, infantile anorexia, and pediatric feeding disorder overlap clinically but are not synonyms unless full diagnostic criteria are met. (fonseca2024avoidantrestrictivefood pages 1-2, nocerino2024developmentandmanagement pages 4-6)

The evidence summarized here is aggregated disease-level literature and trial-registry data, not individual EHR-derived patient data. Individual case reports and clinical cohorts contribute to treatment evidence but should not be treated as population estimates.

2. Etiology, risk, protective factors, and gene–environment interaction

Causal framework

ARFID has no single necessary or sufficient cause. A useful model separates:

1. Predisposing factors: sensory hyperresponsivity, anxiety temperament, ASD, ADHD, GI or neurologic disease, food allergy, and possibly inherited appetite or taste sensitivity.
2. Precipitating factors: choking, vomiting, abdominal pain, allergic reaction or fear of one, painful oral/GI procedures, medication initiation, bullying, bereavement, or other stressful events.
3. Perpetuating factors: conditioned fear and avoidance, relief following food refusal, provision of only preferred foods, reduced exposure to novel foods, parental distress or coercive mealtime interactions, malnutrition-associated early satiety/GI dysmotility, and social withdrawal. In one retrospective cohort summarized by the 2024 review, 71.4% reported an identifiable trigger. (fonseca2024avoidantrestrictivefood pages 4-6)

Food allergy illustrates a plausible gene–environment/medical–behavioral pathway: a genuine adverse reaction produces heightened threat expectancy; avoidance generalizes beyond the allergen to tolerated foods; parental anxiety and limited dietary exposure reinforce fear; and reduced variety produces deficiency and psychosocial impairment. This is clinical observational evidence, not proof that allergy independently causes ARFID. (nocerino2024developmentandmanagement pages 4-6)

Genetic risk

A Swedish twin study published in 2023 reported substantial heritability for a broad pediatric ARFID phenotype, with nonshared environmental effects also contributing. However, the broad phenotype did not fully represent all fear-of-aversive-consequence cases, so it should not be interpreted as the heritability of DSM-5 ARFID in its entirety. Recent reviews mention a chromosome-5 signal near ZSWIM6, but a causal locus or clinically actionable variant has not been validated in the retrieved primary evidence. (tomaszek2025unravelingtheconnections pages 2-4, sanchezcerezo2024subtypesofavoidantrestrictive pages 9-10)

Accordingly:

• Causal genes/pathogenic variants: none established.
• Inheritance: complex, multifactorial/polygenic—not Mendelian.
• Penetrance, carrier frequency, anticipation, founder effects, germline mosaicism: not applicable or unknown.
• ClinVar/ClinGen testing: no ARFID-specific clinically validated gene or panel.
• Modifier genes/epigenetics: no replicated ARFID-specific modifiers or epigenetic signature.
• Somatic variants/chromosomal abnormalities: not features of idiopathic ARFID.

Environmental and lifestyle risks

There is no established toxin, pollutant, radiation, occupational exposure, infection, smoking, alcohol, or exercise exposure that specifically causes ARFID. Relevant “environmental” factors are mainly developmental and experiential: limited early food exposure, adverse feeding experiences, food insecurity as a diagnostic alternative rather than ARFID, family accommodation, and culturally mediated food availability. Food restriction due solely to poverty, famine, neglect, religious observance, or another culturally sanctioned practice excludes ARFID. (sanchezcerezo2024subtypesofavoidantrestrictive pages 3-4)

Protective factors

No genetic protective variant is established. Plausible but incompletely tested protective factors include responsive feeding, repeated noncoercive exposure to varied foods, prompt treatment of pain/allergy/GI disease, accurate allergy education, predictable meals, avoidance of unnecessary elimination diets, parental self-efficacy, and early multidisciplinary intervention. These should be annotated as expert-informed prevention strategies, not proven primary-prevention effects.

3. Phenotypes

Core behavioral phenotypes

1. Sensory sensitivity: rejection based on texture, taste, smell, temperature, color, appearance, brand, or foods touching. It often begins early and may remain stable without intervention. Suggested HPO concepts: Feeding difficulties (HP:0011968), abnormal eating behavior, and sensory hypersensitivity; exact current HPO IDs should be validated before ingestion.
2. Lack of interest/low appetite: little hunger, early satiety, forgetting to eat, small bites, slow or prolonged meals, and low anticipatory reward. Suggested HPO: Poor appetite (HP:0004396) and feeding difficulties.
3. Fear of aversive consequences: acute or subacute avoidance following choking, vomiting, pain, allergic reaction, or invasive procedures; fear may generalize to entire food groups or settings. Suggested HPO: feeding difficulties, anxiety, vomiting, dysphagia/choking where actually present.
4. Mixed/combined presentation: common and clinically important. In 319 UK/ROI cases aged 5–18, classes were Fear 7.2% (23), Lack of Interest 25.1% (80), Sensory 29.5% (94), and Combined 38.2% (122). Younger age, male sex, eating distress, weight loss, and ASD distinguished class membership. (sanchezcerezo2024subtypesofavoidantrestrictive pages 9-10, sanchezcerezo2024subtypesofavoidantrestrictive pages 1-2)

A Swiss school study summarized in the 2024 paper found ARFID features in 3.2%; among these children, 39% reported lack of interest, 60% sensory sensitivity, 15% fear, and 15% multiple presentations. Because dimensions overlap, percentages need not sum to 100%. (sanchezcerezo2024subtypesofavoidantrestrictive pages 2-3)

Physical and laboratory phenotypes

Depending on diet and severity, findings include weight loss or faltering growth, underweight, anemia, hypokalemia, micronutrient deficiencies, fatigue, lethargy, impaired memory, presyncope, constipation, cold intolerance, hypothermia, dry skin, lanugo, alopecia, bradycardia, orthostatic tachycardia/hypotension, delayed puberty, amenorrhea, and low bone mineral density. Oral-motor or speech delay may occur when children have had little experience chewing complex textures. (fonseca2024avoidantrestrictivefood pages 9-10, fonseca2024avoidantrestrictivefood pages 10-12)

Deficiencies depend more on foods omitted than on BMI. Restriction of grains risks inadequate carbohydrate and fiber; animal products/dairy/legumes can reduce protein, riboflavin, B12, iron, selenium, and zinc; fish avoidance can reduce vitamin D and omega-3 intake; fruit/vegetable avoidance can reduce vitamin C and folate; and broad fat restriction can reduce vitamins A, D, E, and K. Normal or high body weight therefore does not exclude significant nutritional deficiency. (fonseca2024avoidantrestrictivefood pages 12-13)

Psychosocial and quality-of-life phenotypes

Patients may be unable to eat at school, restaurants, celebrations, or with peers; may carry preferred foods everywhere; experience tantrums or severe distress; and have excessively long meals, school impairment, restricted peer relationships, and family conflict. These impairments can satisfy Criterion A even without underweight. Standardized ARFID-specific quality-of-life data remain sparse; trials use measures such as the Clinical Impairment Assessment, SF-36, Strengths and Difficulties Questionnaire, and pediatric generic quality-of-life scales. (fonseca2024avoidantrestrictivefood pages 10-12, sanchezcerezo2024subtypesofavoidantrestrictive pages 3-4, NCT04450771 chunk 2)

4. Genetic and molecular information

No causal gene, HGNC-annotated pathogenic variant, ACMG/AMP classification, allele frequency, protein loss/gain of function, or diagnostic structural variant is established for ARFID. WES, WGS, CMA, karyotyping, FISH, mitochondrial sequencing, and repeat-expansion testing are not routine ARFID tests. They are appropriate only when syndromic features, intellectual disability, congenital anomalies, neurologic findings, or another suspected genetic disorder independently warrant investigation.

Molecular profiling is preliminary. There is no replicated disease-defining transcriptomic, proteomic, metabolomic, lipidomic, epigenomic, single-cell, spatial-transcriptomic, multi-omic, or CRISPR-screen signature. This negative annotation is important: ARFID is currently diagnosed phenotypically, not molecularly.

5. Environmental information

No infectious agent or zoonotic transmission is implicated. GI disease, food allergy, pain, vomiting and choking are medical/environmental triggers rather than infectious etiologies. Restrictive diets prescribed for legitimate disease can become disproportionate and impairing; clinicians should distinguish medically necessary avoidance from generalized fear and restriction exceeding medical requirements. In GI populations, reported ARFID-screen positivity varies substantially—approximately 40% in some disorder-of-gut–brain-interaction samples, 17% in IBD, and 6–24% in neurogastroenterology settings—although these figures are not general-population prevalence and may be inflated by symptom overlap or screening methods. (che2025avoidantrestrictivefoodintake pages 13-15)

6. Mechanism and pathophysiology

Three-dimensional model

Sensory pathway: inherited/developmental sensory responsivity and altered integration of taste, smell, touch, and visual food cues → intense aversive experience → selective refusal → reduced exposure and nutritional variety → reinforcement of sensory avoidance. Candidate systems include gustatory/olfactory pathways and insular sensory integration. Taste-receptor variation such as TAS2R-family bitter sensitivity is biologically plausible but not an established ARFID cause. (fonseca2024avoidantrestrictivefood pages 4-6, fonseca2024avoidantrestrictivefood pages 6-7)

Homeostatic/appetite pathway: reduced hunger, early satiation, or low food reward → inadequate meal initiation/maintenance → low intake and growth/weight consequences. Candidate structures include hypothalamus, brainstem, insula, and orbitofrontal reward networks. Preliminary endocrine studies have examined ghrelin, peptide YY, cholecystokinin, and GLP-1; findings are inconsistent and may reflect malnutrition rather than upstream disease. A cited study found higher fasting CCK in full/subthreshold ARFID than controls after adjustment, while low-weight ARFID showed lower meal-related total ghrelin than anorexia nervosa. These remain research findings, not biomarkers. (fonseca2024avoidantrestrictivefood pages 6-7)

Negative-valence/fear pathway: adverse event → amygdala/anterior-cingulate threat learning → anticipatory anxiety and autonomic arousal → avoidance → immediate relief (negative reinforcement) → generalization and chronic restriction. Exposure-based therapies directly target this causal loop. (fonseca2024avoidantrestrictivefood pages 6-7)

A 2023 human study of 71 participants aged 10–23 with full/subthreshold ARFID and 33 controls found lower anticipatory and consummatory pleasure, but group differences disappeared after controlling for depression or removing food items. Within ARFID, greater severity and lack-of-interest symptoms remained associated with lower anticipatory pleasure. Thus, generalized anhedonia is not established; food-specific reward and comorbid depression are important confounders. DOI: https://doi.org/10.1186/s40337-023-00921-w, published November 2023. (dolan2023anticipatoryandconsummatory pages 1-2, dolan2023anticipatoryandconsummatory pages 8-9)

Suggested ontology annotations, treated as mechanistic hypotheses rather than proven disease pathways:

• GO biological processes: sensory perception of taste; sensory perception of smell; feeding behavior; regulation of appetite; response to food; associative learning; fear response; energy homeostasis.
• Cell Ontology: neuron, sensory neuron, neuroendocrine cell, enteroendocrine cell. No ARFID-specific pathogenic cell type is established.
• Anatomy: hypothalamus, insular cortex, orbitofrontal cortex, amygdala, anterior cingulate cortex, brainstem, and GI tract.

7. Anatomical structures affected

ARFID is a functional psychiatric/behavioral syndrome, not a focal tissue lesion. The central nervous system mediates sensory, reward, appetite, and threat processes. The oral cavity/pharynx/esophagus/GI tract may be sites of triggering sensations or comorbid disease. Secondary consequences involve bone, endocrine/reproductive, cardiovascular, integumentary, hematologic, and GI systems through malnutrition.

Suggested UBERON mappings include brain (UBERON:0000955), hypothalamus (UBERON:0001898), amygdala, insular cortex, anterior cingulate cortex, oral cavity, pharynx, esophagus, stomach, small intestine, and bone tissue. There is no expected lateralization. No specific organelle or GO cellular-component defect is known.

8. Temporal development

Onset is commonly pediatric and may be insidious for sensory/lack-of-interest presentations or abrupt after an aversive event for fear-based ARFID. Clinical cohorts often have mean ages around 11.1–14.6 years, but onset can occur in infancy/childhood and persistence into adulthood is well documented. Sensory refusal was more common at younger ages in a 207-patient surveillance sample: 66.7% at 5–9 years, 38.6% at 10–14, and 22.2% at 15–18. (fonseca2024avoidantrestrictivefood pages 2-4, fonseca2024avoidantrestrictivefood pages 6-7)

Course is heterogeneous—stable, progressive, fluctuating, or event-triggered—and no validated disease staging system exists. Compared with anorexia nervosa, ARFID often begins younger and may require longer hospitalization or more enteral support despite similar BMI. Long-term remission, relapse, and transition-to-other-eating-disorder estimates remain inadequately characterized. Comorbidity and entrenched avoidance plausibly predict a more difficult course. (fonseca2024avoidantrestrictivefood pages 10-12, fonseca2024avoidantrestrictivefood pages 14-15)

9. Inheritance and population epidemiology

General-population prevalence is commonly summarized as approximately 0.5–5%, but estimates range from 0.3% to 64% across highly dissimilar community, GI, feeding-clinic, and eating-disorder samples. The only incidence study highlighted in the recent reviews identified 2.02 cases per 100,000 persons aged 5–18 years presenting to pediatricians (95% CI 1.76–2.31). These figures demonstrate methodological heterogeneity rather than true geographic differences. (fonseca2024avoidantrestrictivefood pages 2-4, sanchezcerezo2024subtypesofavoidantrestrictive pages 2-3)

Clinical samples include more boys than classic adolescent eating-disorder cohorts, but ARFID affects all sexes. Reported male proportions range approximately 21–50%. Boys in one surveillance sample had more sensory refusal than girls—51.2% versus 31.5%, p=0.007—whereas fear presentations often skew female. ASD is reported in roughly 13–50% in some clinical literature, while broader reviews report ranges from 8.2% to 54.8%; ascertainment strongly affects these estimates. Anxiety disorders are reported in 9.1–72%. (fonseca2024avoidantrestrictivefood pages 2-4, tomaszek2025unravelingtheconnections pages 2-4, fonseca2024avoidantrestrictivefood pages 4-6, sanchezcerezo2024subtypesofavoidantrestrictive pages 2-3)

There is no established ethnic restriction, endemic region, founder variant, consanguinity effect, carrier state, or population-specific penetrance.

10. Diagnostics

Clinical diagnosis and workup

Diagnosis requires history from patient and caregivers, dietary assessment, growth-chart review, anthropometry, physical examination, psychosocial-functional assessment, and evaluation of body-image motivation. Clinicians should document which Criterion-A consequence is present and characterize all three dimensions rather than forcing one subtype.

Recommended tests are individualized, not diagnostic biomarkers: CBC; electrolytes, renal and hepatic indices; calcium, magnesium and phosphate; glucose; iron/ferritin; B12/folate; vitamin D and other micronutrients suggested by the excluded foods; inflammatory testing where indicated; TSH/free T4; and celiac serology. ECG is appropriate with bradycardia, syncope, electrolyte disturbance, severe malnutrition, or QT-risk medication. Bone-age or DXA assessment may be indicated with growth/puberty delay, prolonged amenorrhea, fractures, or chronic undernutrition. Imaging, endoscopy, swallow study, allergy testing, or motility studies should be driven by clinical indications—not used routinely to “confirm” ARFID. The COUNTERACT trial, for example, required normal thyroid testing and negative celiac screening to exclude medical explanations. (NCT05954728 chunk 1)

Instruments

• PARDI: semistructured diagnostic/severity interview covering the three profiles; reported internal consistency α=0.77–0.89 and diagnostic reliability κ=0.75.
• PARDI-AR-Q: 32-item self/parent questionnaire used for dimensional symptom assessment.
• NIAS: nine-item screen with sensory, appetite, and fear subscales; reported total α=0.84 and ω=0.90. It is a screen, not a stand-alone diagnosis.
• EDA-5, Eating Disorder Examination ARFID module, and EDY-Q are additional approaches depending on age and setting. (fonseca2024avoidantrestrictivefood pages 9-10, NCT05954728 chunk 1)

Differential diagnosis

Exclude anorexia nervosa/atypical AN and bulimia nervosa; food insecurity or cultural/religious restriction; developmentally typical picky eating; food allergy/celiac disease/eosinophilic esophagitis; inflammatory or structural GI disease; dysphagia and oral-motor disorders; gastroparesis and disorders of gut–brain interaction; endocrine/metabolic disease; malignancy or chronic infection; medication adverse effects; depression-related appetite loss; OCD contamination fears; specific phobia of choking/vomiting; psychosis; ASD-associated selectivity not independently meeting ARFID impairment criteria; rumination disorder; and pica. Another disorder can coexist when restriction is disproportionate and independently impairing. (sanchezcerezo2024subtypesofavoidantrestrictive pages 3-4)

There is no asymptomatic newborn, carrier, prenatal, or cascade screening program.

11. Outcome and prognosis

ARFID can produce substantial morbidity through malnutrition, growth failure, electrolyte disturbance, cardiovascular instability, delayed puberty, low bone density, dependence on supplements/tubes, and social or educational disability. Severe refeeding carries risk of potentially fatal refeeding syndrome and requires electrolyte and clinical monitoring. (fonseca2024avoidantrestrictivefood pages 9-10, fonseca2024avoidantrestrictivefood pages 12-13)

Disease-specific mortality, five- or ten-year survival, and life-expectancy estimates are unavailable. Death is biologically possible from severe malnutrition or refeeding complications, but no robust ARFID-specific mortality rate should be entered. Recovery is possible—especially with early, presentation-matched treatment—but long-term remission and relapse probabilities are not well quantified. Potential adverse prognostic factors include severe nutritional compromise, prolonged illness, multiple presentations, ASD/anxiety/OCD/trauma comorbidity, persistent pain or GI disease, tube dependence, family accommodation, and limited specialist access. No prognostic molecular biomarker exists.

12. Treatment

Treatment algorithm

1. Triage medical stability: hospitalize or use higher care for severe bradycardia, hypotension/orthostasis, hypothermia, syncope, serious electrolyte abnormalities, acute food refusal/dehydration, suicidality, or severe malnutrition.
2. Restore nutrition: begin with accepted foods and oral supplements to stabilize energy intake; monitor refeeding risk; add targeted micronutrients.
3. Treat maintaining mechanism: graded sensory exposure and food chaining; interoceptive/appetite work and scheduled eating for lack of interest; exposure/response prevention for fear.
4. Mobilize caregivers and environment: structured meals, reduction of accommodation, school plans, and caregiver coaching.
5. Treat comorbidity and relapse risk: address anxiety, OCD, depression, ASD-related needs, allergy, pain, and GI disease without reinforcing unnecessary avoidance.

A multidisciplinary team may include pediatrics/adolescent medicine, psychiatry/psychology, dietetics, nursing, occupational or speech-language therapy, gastroenterology, and allergy specialists. (nocerino2024developmentandmanagement pages 9-11, fonseca2024avoidantrestrictivefood pages 10-12)

Psychological interventions

CBT-AR is a modular four-stage treatment: psychoeducation/early change, treatment planning, mechanism-focused exposure, and relapse prevention. Youth and adult proof-of-concept studies reported reductions in PARDI severity, increased dietary variety, and weight gain among underweight participants; adult anxiety/depression did not consistently improve. The original MGH pilot enrolled 35 participants aged 10–65 for 20–30 outpatient sessions, but it was uncontrolled. (fonseca2024avoidantrestrictivefood pages 13-14, NCT02963220 chunk 1)

FBT-ARFID externalizes the disorder, empowers caregivers, and focuses behaviorally on changing eating. The Stanford efficacy trial randomized 98 medically stable children aged 6–12 at 75–88% expected body weight to 14 sessions of FBT-ARFID or time-matched nonspecific care over four months, with expected body weight and parental self-efficacy as primary outcomes. This is stronger design evidence, but registry completion does not itself establish superiority until analyzed results are published. Protocol PMID: 36460266; trial: https://clinicaltrials.gov/study/NCT04450771. (NCT04450771 chunk 1, NCT04450771 chunk 2)

Suggested MAXO mappings: cognitive behavioral therapy; family therapy; exposure therapy; dietary counseling; nutritional supplementation; enteral tube feeding; weight monitoring; laboratory monitoring; electrocardiography; psychiatric assessment. Exact MAXO identifiers should be checked against the current ontology release.

Nutrition and enteral support

Dietetic treatment calculates energy/fluid needs, repairs macro- and micronutrient gaps, schedules meals, and gradually expands variety. Oral nutrition is preferred. Enteral feeding can be lifesaving but should generally be medically necessary, goal-directed, and temporary; prolonged use may reduce expectations for oral eating and reinforce avoidance. (fonseca2024avoidantrestrictivefood pages 12-13, fonseca2024avoidantrestrictivefood pages 10-12)

Pharmacotherapy

No medication is FDA-approved specifically for ARFID. Drugs are adjuncts for appetite, anxiety, nausea, rigidity, or comorbidity—not substitutes for nutritional/behavioral treatment. Small reports describe mirtazapine, cyproheptadine, low-dose olanzapine, SSRIs, and buspirone. A small mirtazapine report found mean weekly BMI change increased from 0.10 before treatment to 0.23 after initiation, but confounding and absence of randomization preclude an efficacy claim. Olanzapine may increase appetite and reduce rigidity but has metabolic and neurologic risks. There is no ARFID-specific pharmacogenomic guidance. (fonseca2024avoidantrestrictivefood pages 13-14, fonseca2024avoidantrestrictivefood pages 12-13)

Recent and ongoing implementation research

• NCT05954728 COUNTERACT: double-masked, randomized CBT-AR versus dietitian nutrition counseling; ages 10–18; actual n=53; 15 weeks; outcomes include food neophobia, PARDI, diet, and food-cue fMRI. https://clinicaltrials.gov/study/NCT05954728. (NCT05954728 chunk 1)
• NCT04450771: FBT-ARFID versus nonspecific care; n=98; completed; results publication pending in the retrieved record. https://clinicaltrials.gov/study/NCT04450771. (NCT04450771 chunk 1)
• NCT03778216: randomized crossover feasibility trial of FBT-ARFID in ages 5–12; n=28. https://clinicaltrials.gov/study/NCT03778216. (NCT03778216 chunk 1)
• NCT02963220: single-group CBT-AR pilot; n=35; ages 10–65. Adult outcome paper PMID 34423319. https://clinicaltrials.gov/study/NCT02963220. (NCT02963220 chunk 1, NCT02963220 chunk 2)
• NCT06110806: 20-session family-based mindfulness/interoceptive exposure; only 12 enrolled and the trial was terminated because of failure to agree on a risk-mitigation plan—not demonstrated inefficacy. https://clinicaltrials.gov/study/NCT06110806. (NCT06110806 chunk 1)

No gene, cell, RNA, targeted molecular, immunologic, or surgical therapy is indicated.

13. Prevention

Primary prevention: evidence is insufficient for a population program. Reasonable strategies include responsive/noncoercive feeding, varied age-appropriate exposure, prompt management of pain/dysphagia/allergy, avoidance of unnecessary elimination diets, and caregiver education after choking or allergic events.

Secondary prevention: screen high-risk groups—children with faltering growth, extreme selectivity, ASD/ADHD, anxiety, emetophobia, food allergy, eosinophilic/GI disease, prolonged tube feeding, or marked mealtime distress—and confirm diagnosis early with clinical interview. School and primary-care growth monitoring may detect consequences before severe malnutrition.

Tertiary prevention: monitor growth, diet and micronutrients; prevent refeeding syndrome; minimize prolonged tube dependence; maintain food exposures and relapse plans; address family accommodation and school participation; and monitor bone, pubertal, cardiovascular, and psychiatric complications. There is no vaccine, chemoprophylaxis, carrier screening, or reproductive genetic counseling specific to ARFID.

14. Other species and natural disease

No naturally occurring veterinary disorder equivalent to DSM-defined ARFID was identified. Animals can exhibit neophobia, conditioned taste aversion, sensory selectivity, low appetite, or post-traumatic feeding avoidance, but cannot reproduce the full human diagnosis, particularly self-reported motivation and psychosocial-impairment criteria. Therefore, no NCBI Taxon, VBO breed, orthologous causal gene, zoonotic transmission, or comparative Mendelian-disease annotation should be assigned specifically to ARFID.

15. Model organisms

There is no validated whole-disorder mouse, rat, zebrafish, invertebrate, organoid, or iPSC model. Component models—conditioned taste aversion, bitter-taste sensitivity, fear conditioning, altered appetite hormones, sensory hypersensitivity, or developmental restricted exposure—may test individual mechanisms. Their major limitation is poor construct validity for heterogeneous human motivations, family interactions, culture, language, and functional impairment. No ARFID-specific knockout, knock-in, humanized model, CRISPR screen, or model-organism repository entry was established in the retrieved evidence.

Evidence appraisal and knowledge-base cautions

The most authoritative recent synthesis retrieved was Fonseca et al., published June 2024 in Journal of Eating Disorders, DOI: https://doi.org/10.1186/s40337-024-01021-z. Its conclusion appropriately states that assessment tools and treatments “are still in the process of development and validation.” (fonseca2024avoidantrestrictivefood pages 14-15)

The strongest 2024 primary phenotyping evidence is Sanchez-Cerezo et al.’s national active-surveillance latent-class analysis. Its finding that the combined presentation was most common argues against encoding the three presentations as mutually exclusive disease subtypes. (sanchezcerezo2024subtypesofavoidantrestrictive pages 1-2)

For database population, claims should be graded as follows:

• Established: clinical diagnostic criteria; absence of weight/shape motivation; heterogeneous dimensional presentations; nutritional and psychosocial consequences.
• Moderately supported: associations with ASD, anxiety, ADHD, GI disease and food allergy; sensory/fear/appetite maintenance mechanisms; benefit of structured multidisciplinary care.
• Preliminary: specific neural-circuit and appetite-hormone abnormalities; treatment-response magnitudes; genetic loci.
• Not established/not applicable: monogenic causal genes, pathogenic variants, molecular biomarkers, disease-specific omics signatures, approved pharmacotherapy, validated animal model, mortality rate, or population screening program.

References

1. (fonseca2024avoidantrestrictivefood pages 1-2): Natasha K. O. Fonseca, Vitória D. Curtarelli, Juliana Bertoletti, Karla Azevedo, Tiago M. Cardinal, Júlia D. Moreira, and Luciana C. Antunes. Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment. Journal of Eating Disorders, Jun 2024. URL: https://doi.org/10.1186/s40337-024-01021-z, doi:10.1186/s40337-024-01021-z. This article has 71 citations and is from a peer-reviewed journal.

2. (sanchezcerezo2024subtypesofavoidantrestrictive pages 1-2): Javier Sanchez-Cerezo, Josephine Neale, Nikita Julius, Tim Croudace, Richard M. Lynn, Lee D. Hudson, and Dasha Nicholls. Subtypes of avoidant/restrictive food intake disorder in children and adolescents: a latent class analysis. eClinicalMedicine, 68:102440, Feb 2024. URL: https://doi.org/10.1016/j.eclinm.2024.102440, doi:10.1016/j.eclinm.2024.102440. This article has 54 citations and is from a peer-reviewed journal.

3. (fonseca2024avoidantrestrictivefood pages 13-14): Natasha K. O. Fonseca, Vitória D. Curtarelli, Juliana Bertoletti, Karla Azevedo, Tiago M. Cardinal, Júlia D. Moreira, and Luciana C. Antunes. Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment. Journal of Eating Disorders, Jun 2024. URL: https://doi.org/10.1186/s40337-024-01021-z, doi:10.1186/s40337-024-01021-z. This article has 71 citations and is from a peer-reviewed journal.

4. (fonseca2024avoidantrestrictivefood pages 12-13): Natasha K. O. Fonseca, Vitória D. Curtarelli, Juliana Bertoletti, Karla Azevedo, Tiago M. Cardinal, Júlia D. Moreira, and Luciana C. Antunes. Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment. Journal of Eating Disorders, Jun 2024. URL: https://doi.org/10.1186/s40337-024-01021-z, doi:10.1186/s40337-024-01021-z. This article has 71 citations and is from a peer-reviewed journal.

5. (fonseca2024avoidantrestrictivefood pages 4-6): Natasha K. O. Fonseca, Vitória D. Curtarelli, Juliana Bertoletti, Karla Azevedo, Tiago M. Cardinal, Júlia D. Moreira, and Luciana C. Antunes. Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment. Journal of Eating Disorders, Jun 2024. URL: https://doi.org/10.1186/s40337-024-01021-z, doi:10.1186/s40337-024-01021-z. This article has 71 citations and is from a peer-reviewed journal.

6. (NCT06110806 chunk 2): Robyn Sysko. Family-Based Interoceptive Exposure for Avoidant Restrictive Food Intake Disorder. Icahn School of Medicine at Mount Sinai. 2023. ClinicalTrials.gov Identifier: NCT06110806

7. (fonseca2024avoidantrestrictivefood pages 2-4): Natasha K. O. Fonseca, Vitória D. Curtarelli, Juliana Bertoletti, Karla Azevedo, Tiago M. Cardinal, Júlia D. Moreira, and Luciana C. Antunes. Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment. Journal of Eating Disorders, Jun 2024. URL: https://doi.org/10.1186/s40337-024-01021-z, doi:10.1186/s40337-024-01021-z. This article has 71 citations and is from a peer-reviewed journal.

8. (sanchezcerezo2024subtypesofavoidantrestrictive pages 2-3): Javier Sanchez-Cerezo, Josephine Neale, Nikita Julius, Tim Croudace, Richard M. Lynn, Lee D. Hudson, and Dasha Nicholls. Subtypes of avoidant/restrictive food intake disorder in children and adolescents: a latent class analysis. eClinicalMedicine, 68:102440, Feb 2024. URL: https://doi.org/10.1016/j.eclinm.2024.102440, doi:10.1016/j.eclinm.2024.102440. This article has 54 citations and is from a peer-reviewed journal.

9. (nocerino2024developmentandmanagement pages 4-6): Rita Nocerino, Caterina Mercuri, Vincenzo Bosco, Vincenza Giordano, Silvio Simeone, Assunta Guillari, and Teresa Rea. Development and management of avoidant/restrictive food intake disorder and food neophobia in pediatric patients with food allergy: a comprehensive review. Nutrients, 16:3034, Sep 2024. URL: https://doi.org/10.3390/nu16173034, doi:10.3390/nu16173034. This article has 16 citations.

10. (tomaszek2025unravelingtheconnections pages 2-4): Natalia Tomaszek, Agata Dominika Urbaniak, Daniel Bałdyga, Kamila Chwesiuk, Stefan Modzelewski, and Napoleon Waszkiewicz. Unraveling the connections: eating issues, microbiome, and gastrointestinal symptoms in autism spectrum disorder. Nutrients, 17:486, Jan 2025. URL: https://doi.org/10.3390/nu17030486, doi:10.3390/nu17030486. This article has 36 citations.

11. (fonseca2024avoidantrestrictivefood pages 6-7): Natasha K. O. Fonseca, Vitória D. Curtarelli, Juliana Bertoletti, Karla Azevedo, Tiago M. Cardinal, Júlia D. Moreira, and Luciana C. Antunes. Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment. Journal of Eating Disorders, Jun 2024. URL: https://doi.org/10.1186/s40337-024-01021-z, doi:10.1186/s40337-024-01021-z. This article has 71 citations and is from a peer-reviewed journal.

12. (dolan2023anticipatoryandconsummatory pages 1-2): Sarah C. Dolan, P. Evelyna Kambanis, Casey M. Stern, Kendra R. Becker, Lauren Breithaupt, Julia Gydus, Sarah Smith, Madhusmita Misra, Nadia Micali, Elizabeth A. Lawson, Kamryn T. Eddy, and Jennifer J. Thomas. Anticipatory and consummatory pleasure in avoidant/restrictive food intake disorder. Journal of Eating Disorders, Nov 2023. URL: https://doi.org/10.1186/s40337-023-00921-w, doi:10.1186/s40337-023-00921-w. This article has 13 citations and is from a peer-reviewed journal.

13. (dolan2023anticipatoryandconsummatory pages 8-9): Sarah C. Dolan, P. Evelyna Kambanis, Casey M. Stern, Kendra R. Becker, Lauren Breithaupt, Julia Gydus, Sarah Smith, Madhusmita Misra, Nadia Micali, Elizabeth A. Lawson, Kamryn T. Eddy, and Jennifer J. Thomas. Anticipatory and consummatory pleasure in avoidant/restrictive food intake disorder. Journal of Eating Disorders, Nov 2023. URL: https://doi.org/10.1186/s40337-023-00921-w, doi:10.1186/s40337-023-00921-w. This article has 13 citations and is from a peer-reviewed journal.

14. (fonseca2024avoidantrestrictivefood pages 9-10): Natasha K. O. Fonseca, Vitória D. Curtarelli, Juliana Bertoletti, Karla Azevedo, Tiago M. Cardinal, Júlia D. Moreira, and Luciana C. Antunes. Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment. Journal of Eating Disorders, Jun 2024. URL: https://doi.org/10.1186/s40337-024-01021-z, doi:10.1186/s40337-024-01021-z. This article has 71 citations and is from a peer-reviewed journal.

15. (fonseca2024avoidantrestrictivefood pages 10-12): Natasha K. O. Fonseca, Vitória D. Curtarelli, Juliana Bertoletti, Karla Azevedo, Tiago M. Cardinal, Júlia D. Moreira, and Luciana C. Antunes. Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment. Journal of Eating Disorders, Jun 2024. URL: https://doi.org/10.1186/s40337-024-01021-z, doi:10.1186/s40337-024-01021-z. This article has 71 citations and is from a peer-reviewed journal.

16. (sanchezcerezo2024subtypesofavoidantrestrictive pages 3-4): Javier Sanchez-Cerezo, Josephine Neale, Nikita Julius, Tim Croudace, Richard M. Lynn, Lee D. Hudson, and Dasha Nicholls. Subtypes of avoidant/restrictive food intake disorder in children and adolescents: a latent class analysis. eClinicalMedicine, 68:102440, Feb 2024. URL: https://doi.org/10.1016/j.eclinm.2024.102440, doi:10.1016/j.eclinm.2024.102440. This article has 54 citations and is from a peer-reviewed journal.

17. (NCT05954728 chunk 1): Jennifer Thomas. Cognitive-behavioral Therapy vs. Nutrition Counseling for Avoidant/Restrictive Food Intake Disorder. Massachusetts General Hospital. 2024. ClinicalTrials.gov Identifier: NCT05954728

18. (NCT04450771 chunk 1): James Dale Lock. Confirming the Efficacy/Mechanism of Family Therapy for Children With Low Weight ARFID. Stanford University. 2020. ClinicalTrials.gov Identifier: NCT04450771

19. (NCT03778216 chunk 1): James Dale Lock. Treating Avoidant/Restrictive Food Intake Disorder (ARFID) Using Family-Based Treatment. Stanford University. 2017. ClinicalTrials.gov Identifier: NCT03778216

20. (NCT02963220 chunk 1): Jennifer Thomas. Cognitive-Behavioral Therapy for Avoidant/Restrictive Food Intake Disorder: A Treatment Development and Pilot Study. Massachusetts General Hospital. 2016. ClinicalTrials.gov Identifier: NCT02963220

21. (NCT06110806 chunk 1): Robyn Sysko. Family-Based Interoceptive Exposure for Avoidant Restrictive Food Intake Disorder. Icahn School of Medicine at Mount Sinai. 2023. ClinicalTrials.gov Identifier: NCT06110806

22. (fonseca2024avoidantrestrictivefood pages 14-15): Natasha K. O. Fonseca, Vitória D. Curtarelli, Juliana Bertoletti, Karla Azevedo, Tiago M. Cardinal, Júlia D. Moreira, and Luciana C. Antunes. Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment. Journal of Eating Disorders, Jun 2024. URL: https://doi.org/10.1186/s40337-024-01021-z, doi:10.1186/s40337-024-01021-z. This article has 71 citations and is from a peer-reviewed journal.

23. (sanchezcerezo2024subtypesofavoidantrestrictive pages 9-10): Javier Sanchez-Cerezo, Josephine Neale, Nikita Julius, Tim Croudace, Richard M. Lynn, Lee D. Hudson, and Dasha Nicholls. Subtypes of avoidant/restrictive food intake disorder in children and adolescents: a latent class analysis. eClinicalMedicine, 68:102440, Feb 2024. URL: https://doi.org/10.1016/j.eclinm.2024.102440, doi:10.1016/j.eclinm.2024.102440. This article has 54 citations and is from a peer-reviewed journal.

24. (NCT04450771 chunk 2): James Dale Lock. Confirming the Efficacy/Mechanism of Family Therapy for Children With Low Weight ARFID. Stanford University. 2020. ClinicalTrials.gov Identifier: NCT04450771

25. (che2025avoidantrestrictivefoodintake pages 13-15): Yunqiu Che, Shuhua Li, Xiaju Hu, Hongyan Hu, Can Zhang, and Chaozhu He. Avoidant/restrictive food intake disorder in adult patients with gastrointestinal diseases: a concept analysis using evolutionary approach. Risk Management and Healthcare Policy, 18:2063-2080, Jun 2025. URL: https://doi.org/10.2147/rmhp.s520802, doi:10.2147/rmhp.s520802. This article has 6 citations and is from a peer-reviewed journal.

26. (nocerino2024developmentandmanagement pages 9-11): Rita Nocerino, Caterina Mercuri, Vincenzo Bosco, Vincenza Giordano, Silvio Simeone, Assunta Guillari, and Teresa Rea. Development and management of avoidant/restrictive food intake disorder and food neophobia in pediatric patients with food allergy: a comprehensive review. Nutrients, 16:3034, Sep 2024. URL: https://doi.org/10.3390/nu16173034, doi:10.3390/nu16173034. This article has 16 citations.

27. (NCT02963220 chunk 2): Jennifer Thomas. Cognitive-Behavioral Therapy for Avoidant/Restrictive Food Intake Disorder: A Treatment Development and Pilot Study. Massachusetts General Hospital. 2016. ClinicalTrials.gov Identifier: NCT02963220

Artifacts

• Edison artifact artifact-00